Anaplastic Large Cell Lymphoma Alk-positive

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas [Phase 1]

  Phase 1 clinical trial update for constitutive IL7R (C7R) modified banked allogeneic CD30.CAR EBVSTs in CD30-positive lymphomas, currently r…

• CLINICAL_TRIALS trial_result · 2023-08-07
  Clinical Trial Update: A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma [Phase 2]

  Phase 2 study evaluating oral lorlatinib in patients with relapsed ALK-positive anaplastic large cell lymphoma.

• CLINICAL_TRIALS trial_result · 2023-04-19
  Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma [Phase 2]

  Phase 2 trial evaluating brentuximab vedotin in combination chemotherapy for CD30-positive peripheral T-cell lymphomas reports results poste…

• CLINICAL_TRIALS trial_result · 2023-03-06
  Clinical Trial Update: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas [Phase 2]

  Phase 2 pilot study update of crizotinib in relapsed ALK-positive anaplastic large cell lymphoma.

• CLINICAL_TRIALS trial_result · 2021-06-18
  Clinical Trial Update: Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

  A Phase 1/2 trial evaluating combination chemotherapy with lenalidomide in newly diagnosed peripheral T-cell lymphoma (multiple subtypes) ha…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2014-06-27
  Clinical Trial Update: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma [Phase 2]

  A completed Phase 2 study evaluating the combination of bortezomib and panobinostat in relapsed or refractory peripheral T-cell lymphomas an…